{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-015451","form_type":"8-K","ticker":"ABEO","cik":"0000318306","company_name":"ABEONA THERAPEUTICS INC.","filed_at":"2026-04-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.557694+00:00","generated_at":"2026-05-15T07:10:26.620045+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Abeona Therapeutics appoints Keith Goldan as new independent Board member and Audit Committee Chair","bullets":["Board expanded from 9 to 10 members; Goldan appointed as Class 1 director effective April 1, 2026.","Goldan named Chair of Audit Committee; Board determined independence under Nasdaq rules.","Compensation: $50,000 annual cash fee and $150,000 one-time sign-on RSU grant with one-year vesting.","Goldan currently CFO of Syndax Pharmaceuticals; previously CFO at Optinose and Fibrocell."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-015451","json":"https://secwatch.observer/filing/0001493152-26-015451.json","markdown":"https://secwatch.observer/filing/0001493152-26-015451.md","text":"https://secwatch.observer/filing/0001493152-26-015451.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/318306/000149315226015451/0001493152-26-015451-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/318306/000149315226015451/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T07:10:26.620045+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}